<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362186">
  <stage>Registered</stage>
  <submitdate>5/03/2012</submitdate>
  <approvaldate>6/03/2012</approvaldate>
  <actrnumber>ACTRN12612000266864</actrnumber>
  <trial_identification>
    <studytitle>Outcomes of 400 versus 600 micrometer spot size after single session multispots pattern  scan panretinal photocoagulation</studytitle>
    <scientifictitle>The macular thickness changes after single session multispots pattern scan panretinal photocoagulation with 400 versus 600 micrometer spot size in severe diabetic retinopathy, randomized clinical trial</scientifictitle>
    <utrn>U1111-1128-8868</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>severe diabetic retinopathy (severe nonproliferative and proliferative diabetic retinopathy)</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: multispots pattern panretinal photocoagulation using 400 micrometer spot size
Arm 2: multispots pattern panretinal photocoagulation using 600 micrometer spot size
Laser photocoagulation is performed using pattern scan system (Valon pattern laser, Dual laser LTD OY, Vantaa, Finland), which is a Nd-YAG 532 nm laser beam.  The parameters are: 1) spot sizes of 200 or 300 micrometer with superquad 160 contact lens (laser spot magnification of 2.0; Volk Optical Inc., Mentor, OH) which equivalent to the retinal lesion size of 400 and 600 micrometer, respectively, 2) duration of 20 ms, 3) grid pattern of 4x4, 4) spot spacing of 1.5 widths apart, 5) intensity of gray-white burn, titrated at the major vascular area, 6) distribution extended from vascular arcade to beyond equator, no closer than 2 disc diameter temporal to fovea, no closer  than 1 disc diameter to the nasal optic disc. All treatments are performed under topical anesthesia. Duration of the procedures are approximately 4 to 6 minutes. The re-treatment will be considered at 3 months and 6 months of follow-up. The indications of retreatment are persistence or recurrence of the neovascularization.</interventions>
    <comparator>Control: multispots pattern panretinal photocoagulation using 400 micrometer spot size</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Macular thickness changes after multispots patter photocoagulation in both groups.
Retinal thickness measurements are performed with SD-OCT (Spectralis; Heidelberg Engineering, CA, USA). Scans are performed in fast high resolution pattern, 1024 x 526 resolution.  All scans will be reviewed for the accuracy and manually adjusted by one investigator.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Visual acuity changes after multispots patter photocoagulation in both groups.
Visual acuity will be recorded in ETDRS letters measured at 6-meter charts.</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>severe diabetic retinopathy without macular edema (macular thickness of less than 350 micrometers by SD-OCT)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous intraocular surgery
macular thickness before treatment more than 350 micrometers by SD-OCT
Associated disease affecting visual acuity
Hemoglobin A1c more than 15</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>1:1 permuted block allocation to 400 micrometer spot size group or 600 micrometer spot size group were performed by one ophthalmologist who does not involved in this research. The alllocation are kept in the sealed opaque enveloped and only exposed by 1 technician not involved in the study.</concealment>
    <sequence>Permuted block randomization stratified by sex</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Nil</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/02/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Janejit Choovuthayakorn</primarysponsorname>
    <primarysponsoraddress>110 Intavarorod Road
Maung 
Chiang Mai 
Thailand
5010</primarysponsoraddress>
    <primarysponsorcountry>Thailand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Chiang Mai University Hospital</fundingname>
      <fundingaddress>110 Intavarorod Road
Maung 
Chiang Mai 
Thailand
5010</fundingaddress>
      <fundingcountry>Thailand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Nawat Watanachai</sponsorname>
      <sponsoraddress>110 Intavarorod Road
Maung 
Chiang Mai 
Thailand
5010</sponsoraddress>
      <sponsorcountry>Thailand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Long pulse duration pan retinal photocoagulation has been demonstrated the retinal structure damaged and extensive scar after treatment. The treatment should divided into two sessions to reduce the risk of macular edema. With the new concept of shorter pulse duration for panretinal photocoagulation, the expectency of less tissue damage and less chance of macular edema developed after treatment. The laser session may reduce into one session.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Chiang Mai University Hospital Ethic committee</ethicname>
      <ethicaddress>110 Inravarorod Road
Maung
Chiang Mai 
Thailand
50100</ethicaddress>
      <ethicapprovaldate>9/12/2011</ethicapprovaldate>
      <hrec>OPT-11-09-14-13</hrec>
      <ethicsubmitdate />
      <ethiccountry>Thailand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nawat Watanachai</name>
      <address>110 Intavarorod Road
Maung 
Chiang Mai
Thailand
50100</address>
      <phone>+ 66 94 5512</phone>
      <fax>+ 66 94 6121</fax>
      <email>nwwatanachai@gmail.com</email>
      <country>Thailand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Janejit Choovuthayakorn</name>
      <address>110 Intavarorod Road
Maung
Chiang Mai
Thailand
50100</address>
      <phone>+66 53 94 5512</phone>
      <fax>+66 53 94 6121</fax>
      <email>janjitc@yahoo.com</email>
      <country>Thailand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>